摘要
目的 探讨低分子肝素在经皮冠状动脉成形术 (PCI)中应用的有效性和安全性。方法 将北京安贞医院心肺血管疾病抢救中心 2 0 0 1年 1 0月至 2 0 0 3年 1 1月收治的共 6 0 7例行PCI术的患者分为两组。A组为PCI术中常规用普通肝素 ,B组为术中用体重校正低分子肝素 (enoxaparin ,商品名 :克赛 )。A组 31 1例 ,其中男 2 0 3例 ,女 1 0 8例 ,平均年龄 (6 5 6± 4 0 )岁。B组 2 96例 ,其中男 2 0 0例 ,女 96例 ,平均年龄 (6 7 1± 3 5 )岁。结果 两组的一般临床资料比较差异无显著性。A组与B组手术成功率 (98 4%与 98 0 %)、30d内再次血运重建 (3例与 2例 )、30d内主要心血管不良事件 (各 2例 )、急性血栓形成 (均为 0例 )和周围血管并发症 (8例与 4例 )比较差异均无显著性 (P >0 0 5 )。结论 低分子肝素在PCI术中的应用是有效的、安全的。
Objective To investigate the effectiveness and safety of low-molecular-weight heparins application in PCI. Methods 607 PCI patiens who were hospitalized from Oct. 2001 to Nov. 2003 in Anzhen Hospital with divided into two groups which were group A (using common depo-heparin), and group B (using low-molecular-weight heparins, enoxaparin). There were 311 patiens in group A (203 males and 108 females, average age 65.6±4.0) and 296 patiens in group B (200 males and 96 females, average age 67.1±3.5). Results Clinical data obtained from the two groups has no significant difference (P>0.05). The success rate of operation(98.4% vs 98.0%), target vessel revascularization within 30 days (3 vs 2 patients), major adverse cardiovascular event within 30 days (2 patients in both groups), acute thrombosis (0 patients in both groups) and peripheral vascular complications (8 vs 4 patients) of the two groups have no significant difference (P>0.05). Conclusion Using low-molecular-weight heparins in PCI is effective and safe.
出处
《中国介入心脏病学杂志》
2005年第1期23-24,共2页
Chinese Journal of Interventional Cardiology
